Cumberland Pharmaceuticals Inc. (CPIX)

US — Healthcare Sector
Peers: TKNO  GHSI  LFCR  ORGO  PTPI  ISPC  GRTX  BFRI 

Automate Your Wheel Strategy on CPIX

With Tiblio's Option Bot, you can configure your own wheel strategy including CPIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CPIX
  • Rev/Share 2.7494
  • Book/Share 1.8966
  • PB 1.6008
  • Debt/Equity 0.3643
  • CurrentRatio 1.2491
  • ROIC -0.0709

 

  • MktCap 45930577.0
  • FreeCF/Share 0.3575
  • PFCF 8.5971
  • PE -14.001
  • Debt/Assets 0.1493
  • DivYield 0
  • ROE -0.1277

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
CPIX
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients NASHVILLE, Tenn. , June 23, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Las Vegas.

Read More
image for news Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
CPIX
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executive Officer Todd Anthony – Vice President-Organizational Development John Hamm – Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Fourth Quarter 2024 Financial Report and Company Update.

Read More
image for news Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

About Cumberland Pharmaceuticals Inc. (CPIX)

  • IPO Date 2009-08-11
  • Website https://www.cumberlandpharma.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO A. J. Kazimi MBA
  • Employees 91
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.